High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 39, Issue 1, 2005, Pages 23-31

  Ostrowski, Sisse Rye ^a   Piironen, Timo ^b   Høyer Hansen, Gunilla ^b   Gerstoft, Jan ^a   Pedersen, Bente Klarlund ^a   Ullum, Henrik ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

HIV; Immune activation; Intact and cleaved soluble urokinase receptor; Mortality; Progression; Urokinase receptor

Indexed keywords

UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE RECEPTOR TYPE I; UROKINASE RECEPTOR TYPE II; UROKINASE RECEPTOR TYPE III; VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL;

ADULT; ANALYSIS OF VARIANCE; ANTIGENS, CD; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, CELL SURFACE; REFERENCE VALUES; REGRESSION ANALYSIS; RNA, VIRAL; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 18144395419     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000157950.02076.a6     Document Type: Article

References (60)

1. Ostrowski SR, Katzenstein TL, Piironen T, et al. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004; 35:337-342.
2. Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96: 4091-4095.
3. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis Proteolysis. 1998;12:191-204.
4. Nykjaer A, Moller B, Todd RF, et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994;152:505-516.
5. Nykjaer A, Petersen CM, Moller B, et al. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett. 1992;300:13-17.
6. Plesner T, Ralfkiaer E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994;102:835-841.
7. Haddock RC, Spell ML, Baker CD III, et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 1991; 266:21466-21473.
8. Wohn KD, Kanse SM, Deutsch y et al. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost. 1997;77:540-547.
9. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. MedRes Rev. 2004; 24:13-39.
10. Hoyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:18224-18229.
11. Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991;266: 1926-1933.
12. Wilhelm OG, Wilhelm S, Escott GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol. 1999;180:225-235.
13. De Witte H, Sweep F, Brunner N, et al. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. Int J Cancer. 1998;77:236-242.
14. Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett. 2000;475:52-56.
15. Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res. 2000; 60:7126-7132.
16. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714-724.
17. Blasi F, Carmeliet P uPAR: a versatile signalling orchestraler. Nat Rev Mol Cell Biol. 2002;3:932-943.
18. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004;25:450-455.
19. Mizukami IF, Faulkner NE, Gyetko MR, et al. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood. 1995;86:203-211.
20. Florquin S, van den Berg JG, Olszyna DP, et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 2001;59:2054-2061.
21. Wittenhagen P, Kronborg G, Weis N, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteriemia and predicts mortality. Clin Microbiol Infect. 2004;10:409-415.
22. Eugen-Olsen J, Gustafson P, Sidenius N, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002;6:686-692.
23. Slot O, Brunner N, Locht H, et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999;58:488-492.
24. Riisbro R, Christensen IJ, Piironen T, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res. 2002;8:1132-1141.
25. Riisbro R, Piironen T, Brunner N, et al. Measurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay. 2002;25:53-56.
26. Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol. 1996;70:4451-4456.
27. Wada M, Wada NA, Shirono H, et al. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Commun. 2001;284:346-351.
28. Alfano M, Sidenius N, Panzeri B, et al. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci USA. 2002;99:8862-8867.
29. Ullum H, Gøtzsche PC, Victor J, et al. Defective natural immunity: an early manifestation of human immune deficiency virus infection. J Exp Med. 1995;182:789-799.
30. Ostrowski SR, Gerstoft J, Pedersen BK, et al. Impaired production of cytokines is an independent predictor of mortality in HIV-1-infected patients. AIDS. 2003;17:521-530.
31. Piironen T, Laursen B, Paas J, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem. 2004; 50:259-268.
32. Ploug M, Ostergaard S, Gardsvoll H, et al. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry. 2001;40:12157-12168.
33. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41: 1-19.
34. Cozzi LA, Katzenstein TL, Ullum H, et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS. 1998;12:1639-1643.
35. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
36. Hoyer-Hansen G, Pessara U, Holm A, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J. 2001;358:673-679.
37. Mustjoki S, Sidenius N, Vaheri A. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. FEBS Lett. 2000;486:237-242.
38. Fazioli F, Resnati M, Sidenius N, et al. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279-7286.
39. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15:1572-1582.
40. May AE, Kanse SM, Lund LR, et al. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med. 1998;188: 1029-1037.
41. Dekkers PE, ten Hove T, te Velde AA, et al. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia. Infect Immun. 2000;68:2156-2160.
42. Juffermans NP, Dekkers PE, Verbon A, et al. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun. 2001;69:5182-5185.
43. Yoshida E, Tsuchiya K, Sugiki M, et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation. 1996;20:319-326.
44. Sitrin RG, Todd RF III, Mizukami IF, et al. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood. 1994;84:1268-1275.
45. Chavakis T, Willuweit AK, Lupu F, et al. Release of soluble urokinase receptor from vascular cells. Thromb Haemost. 2001;86:686-693.
46. Stevenson M. HIV-1 pathogenesis. Nat Med. 2003;9:853-860.
47. Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad, or both? J Clin Invest. 2004;113:808-810.
48. Wang L, Robb CW, Cloyd MW. HIV induces homing of resting T lymphocytes to lymph nodes. Virology. 1997;228:141-152.
49. Wang L, Chen JJ, Gelman BB, et al. A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors. J Immunol. 1999; 162:268-276.
50. Grossman Z, Meier-Schellersheim M, Sousa AE, et al. CD4+ T-cell depletion in HIV infection: are we closer to understanding the cause? Nat Med. 2002;8:319-323.
51. Hengel RL, Jones BM, Kennedy MS, et al. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. J Immunol. 1999;163:3539-3548.
52. Plesner T, Ploug M, Ellis V, et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood. 1994;83:808-815.
53. Mizukami IF, Todd RF. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells. J Leukoc Biol. 1998;64:203-213.
54. Wei Y, Lukashev M, Simon DI, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551-1555.
55. Tarui T, Mazar AP, Cines DB, et al. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem. 2001;276:3983-3990.
56. Furlan F, Orlando S, Laudanna C, et al. The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci. 2004;117:2909-2916.
57. Wilhelm O, Weidle U, Hohl S, et al. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994;337:131-134.
58. Kruger A, Soeltl R, Lutz V, et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther. 2000;7: 292-299.
59. Lutz V, Reuning U, Kruger A, et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem. 2001; 382:789-798.
60. Riisbro R, Christensen IJ, Hogdall C, et al. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001;16:233-239.